Dr. Sylvia Mina Lee, MD

Dr. Lee practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Dr. Lee's NPI, 1467465070, was assigned on August 14, 2006. Dr. Lee graduated from University of North Carolina at Chapel Hill School of Medicine in 2003. Dr. Lee holds Washington license ML20007775.

Dr. Lee's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Dr. Lee's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. Dr. Lee is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lee practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Lee's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Lee is licensed in Washington.

CMS data shows 559 Medicare services from Dr. Lee across 8 procedure codes in 2024, for 164 Medicare patients. Medicare paid $47,919 for them.

CMS counts 164 Medicare patients who saw Dr. Lee in 2024. The largest group is 65 to 74, with 83 patients. 67% of them have high blood pressure, and 62% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.24, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lee's median patient age at 71, with 47% women.

In 2024, Dr. Lee wrote 80 Medicare Part D claims for 30 patients. 69% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $53 in total drug cost. In 2023, CMS named 46 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Lee for performance year 2024, reported through an alternative payment model (APM). Dr. Lee accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lee as offering telehealth.

Dmand AI links 41 papers to Dr. Lee, published from 2011 to 2025. 2019 was the busiest year, with 5. The most frequent topics are Immune Checkpoint Inhibitors, Lung Neoplasms and Carcinoma, Non-Small-Cell Lung. Dr. Lee has published most often in Clin Cancer Res. Dr. Lee's most frequent co-authors are Christina Seung Baik, MD, Keith David Eaton, MD and Shailender Bhatia, MD.

Dmand AI links Dr. Lee to 7 clinical trials, 4 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Melanoma, Carcinoma, Transitional Cell and Fallopian Tube Diseases. Fred Hutchinson Cancer Center sponsors the most, 2.

CMS Open Payments shows 4 general payments to Dr. Lee from 4 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 92% of the total. GlaxoSmithKline, LLC. paid the most, $124. It also lists 2 research payments totaling $1,270 in 2025.

Dr. Lee graduated from University of North Carolina at Chapel Hill School of Medicine in 2003.